Please login to the form below

Not currently logged in
Email:
Password:

liso-cel

This page shows the latest liso-cel news and features for those working in and with pharma, biotech and healthcare.

FDA approves BMS’ blood cancer CAR T therapy after delay

FDA approves BMS’ blood cancer CAR T therapy after delay

The US Food and Drug Administration (FDA) has finally approved Bristol Myers Squibb’s (BMS) CAR T-cell therapy Breyanzi, previously known as liso-cel, after delaying the decision in November

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    11. Liso-cel for large B-cell lymphoma is being developed by Bristol-Myers Squibb to treat large B-cell lymphomas, and a filing in the third-line setting is being ... Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of

  • Deal Watch January 2018

    Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017 (liso-cel), CD19-directed CAR-T in pivotal trials for DLBCL.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....